⌘+K

Pulse Explore Clubs Researchers Journals

Home Clubs Explore

January 14, 2019European Journal of CancerOpen Access

NAPOLI-1 phase 3 study of liposomal irinotecan in metastatic pancreatic cancer: Final overall survival analysis and characteristics of long-term survivors

View Full Paper

Ask AI

Bookmark

Share

No abstract yet

We only have this paper's title and publication details.

Read it at the source→

Abstract

Nct01494506.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Wang‐Gillam et al. (2019) studied this question.

synapsesocial.com/papers/69d70f295413bc3de5ab351b https://doi.org/10.1016/j.ejca.2018.12.007

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Modelling prognostic factors in advanced pancreatic cancerPrognostic Study · 2008 · 141 citations
2Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus GemcitabineOriginal Research · 2013 · 6,850 citations
3Beyond first-line chemotherapy for advanced pancreatic cancer: An expanding array of therapeutic options?Human Clinical Trial · 2014 · 61 citations
4Preclinical Activity of Nanoliposomal Irinotecan Is Governed by Tumor Deposition and Intratumor Prodrug ConversionOriginal Research · 2014 · 197 citations
5FOLFIRINOX Chemotherapy in Metastatic Pancreatic Cancer: A Systematic Review and Meta-Analysis of Retrospective and Phase II StudiesMeta-Analysis · 2018 · 54 citations